CN Mobile Logo

Search form


Bryant Furlow

Bryant Furlow

Posts by Author

Pembrolizumab is well-tolerated and shows promising antitumor activity and early survival rates among patients with PD-L1–positive cervical squamous cell cancer, according to preliminary results of the KEYNOTE-028 trial.

Adding metformin to a combination of everolimus plus letrozole for women with advanced or recurrent endometrioid endometrial cancer might offer clinical benefits.

Hormone maintenance therapy is associated with better survival than post-treatment surveillance for women with low-grade serous carcinoma of the ovary or peritoneum.

Combined therapy with gemcitabine and pazopanib appears to be a viable treatment option for patients with soft-tissue sarcomas refractory to anthracycline or ifosfamide.

Elderly patients with stage III non–small-cell lung cancer experience poorer overall survival than patients younger than age 70 years when treated with standard concurrent chemoradiotherapy, according to a pooled analysis.

A targeted-sequencing gene panel that includes EGFR, KRAS, PIK3CA, and other mutations from circulating tumor DNA detects stage I non–small-cell lung cancer and might outperform existing tumor markers.

Regorafenib is associated with improved progression-free survival in pretreated patients with advanced refractory non-liposarcoma soft-tissue sarcomas.

Busulfan/melphalan high-dose chemotherapy consolidation is associated with better survival vs VAI among patients with localized high-risk Ewing sarcoma.

Matching targeted therapies to genetic abnormalities harbored by tumor types for which those therapies are not approved by the FDA might expand treatment options for some patients with advanced cancers.

Directly engaging and recruiting patients online using social media will allow broader participation in cancer genomics research and hasten clinical advances.


By clicking Accept, you agree to become a member of the UBM Medica Community.